FDA Moves to Ban Compounded GLP-1 Drugs, Threatening TomorrowsRx Business Model
The FDA plans to restrict compounding of semaglutide and tirzepatide as brand-name shortages resolve, eliminating the regulatory pathway that allows TomorrowsRx and similar telehealth platforms to offer cheaper weight-loss alternatives. The action targets a market that emerged during Ozempic and Wegovy supply disruptions. TomorrowsRx faces catastrophic revenue risk as compounded GLP-1s form its core product offering.
ViaNews Editorial Team (Markets)•